Resultados de procura - Anne‐Laure Clairet

  • Mostrando 1 - 4 Resultados de 4
Limitar resultados
  1. 1
    Terminal Care in Parkinson’s Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort

    Terminal Care in Parkinson’s Disease: Real-Life Use of Continuous Subcutaneous Apomorphine Infusion to Improve Patient Comfort por Matthieu Béreau, Mathilde Giffard, Anne‐Laure Clairet, Guillaume Degenne, Laurent Tatu, Edward Richfield, Éloi Magnin, Marc Vérin, Manon Auffret

    Publicado 2024
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity

    COVID-19 patients display distinct SARS-CoV-2 specific T-cell responses according to disease severity por Marie Kroemer, Laurie Spehner, Lucie Vettoretti, Adeline Bouard, Guillaume Eberst, Sébastien Pili Floury, Gilles Capellier, Quentin Lepiller, Émeline Orillard, Laura Mansi, Anne‐Laure Clairet, Virginie Westeel, Samuel Limat, Maxime Dubois, Léa Malinowski, L. Bohard, Christophe Borg, Catherine Chirouze, Kévin Bouiller

    Publicado 2020
    Ligazón do recurso Ligazón do recurso
    Carta
    Engadir a favoritos
    Gardado en:
  3. 3
    A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study

    A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 TH1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study por Magali Rebucci-Peixoto, Angélique Vienot, Olivier Adotévi, Marion Jacquin, François Ghiringhelli, Christelle de la Fouchardière, Benoît You, Tristan Maurina, Elsa Kalbacher, Fernando Bazán, Guillaume Meynard, Anne‐Laure Clairet, Christine Fagnoni-Legat, Laurie Spehner, Adeline Bouard, Déwi Vernerey, Aurélia Meurisse, Stéfano Kim, Christophe Borg, Laura Mansi

    Publicado 2022
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)

    Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomi... por Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, Dimitri Pureur, François Ghiringhelli, Eric Assénat, Pascal Hammel, Olivier Rosmorduc, Morgane Stouvenot, Manon Allaire, Mohamed Bouattour, Hélène Regnault, Serge Fratté, Éric Raymond, Émilie Soularue, Stéphanie Husson-Wetzel, Vincent Di Martino, Allison Muller, Anne‐Laure Clairet, Christine Fagnoni-Legat, Olivier Adotévi, Aurélia Meurisse, Déwi Vernerey, Christophe Borg

    Publicado 2023
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: